BILLS-117hr3761ih.pdf

2021 22:12 Jul 13 2-year annual 3 months 6 months 30-day 90 days annually later than 3 weeks 6 years JUNE 8, 2021 each day 180 days every 2 years 1ST SESSION H. R. 3761 18 months up to 6 years later than 1 week

the ‘‘Promising Pathway

PO 00000 PO 00000 Frm 00005 PO 00000 Frm 00006 PO 00000 Frm 00007 PO 00000 Frm PO 00000 Frm 00017 PO 00000 Frm 00019 PO 00000 Frm 00009 PO 00000 Frm 00003 Fmt PO 00000 Frm 00015 PO 00000 Frm 00001 PO 00000 Frm 00018 PO 00000 Frm 00004 PO 00000 Frm 00008 Fmt PO 00000 Frm 00020 PO 00000 Frm 00002 PO 00000 Frm 00016 PO 00000 Frm 00013 Fmt PO 00000 Frm 00010 PO 00000 Frm 00011 Fmt

the United States of America

DSKJLVW7X2PROD with BILLS FDA the Public Health Service Act SEC the Food and Drug Adminis- the Federal Food, Drug Congress thor the Advisory Committee Senate Energy and Commerce the U.S. Food and Drug Administration the Federal Government DRUGS.—A PROVISIONAL THE HOUSE OF REPRESENTATIVES Health and Human Services Disease Control and Prevention Federal Food, Drug the Office of the State the Public Health Service CATIONS the Department of Health health care journal House of Representa-

GALLAGHER QUIGLEY WESTERMAN

pathway drug biological biological products approval biological biological product drugs fda drug products proval establishes reviewed product applications